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Objectives We aimed to investigate the long-term prognosis of patients with in-hospital major bleeding (IHMB).
Background The effect of IHMB on the long-term prognosis of patients undergoing primary percutaneous coronary interven-
tion (PCI) for ST-segment elevation myocardial infarction is unknown.
Methods Primary PCI was performed in 3,345 (92.9%) of 3,602 patients in the HORIZONS-AMI (Harmonizing Outcomes
With Revascularization and Stents in Acute Myocardial Infarction) trial; in-hospital protocol-defined non–coronary
artery bypass graft–related major bleeding developed in 231 (6.9%). We examined medication use at discharge,
mortality, and major adverse cardiovascular events (composite of death, reinfarction, stroke, or ischemic target
vessel revascularization) at 3-year follow-up in patients with and without IHMB.
Results At 3-year follow-up, patients with IHMB had higher mortality (24.6% vs. 5.4%, p  0.0001) and major adverse
cardiovascular events (40.3% vs. 20.5%, p  0.0001). The deleterious effect of major bleeding was observed
within 1 month, between 1 month and 1 year, and between 1 and 3 years. IHMB was an independent predictor
of mortality (hazard ratio: 2.80; 95% confidence interval: 1.89 to 4.16, p  0.0001) at 3-year follow up.
Conclusions Patients with IHMB after primary PCI have significantly increased 3-year rates of morbidity and mortality. Further
investigation is warranted to understand the mechanisms underlying this relationship and to further improve
outcomes in patients with ST-segment myocardial infarction. (Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966) (J Am Coll Cardiol 2011;58:
1750–6) © 2011 by the American College of Cardiology Foundation
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October 18, 2011:1750–6 Impact of In-Hospital Bleeding on Late OutcomeAlthough potent antiplatelet agents and early revasculariza-
tion have improved the prognosis for patients with acute
myocardial infarction (MI), bleeding complications may
result in substantial morbidity or mortality. Major bleeding
See page 1757
has been identified as an independent risk factor for mortality
after acute MI (1,2). Previous reports have suggested that
major bleeding in patients with acute coronary syndromes
treated with an early invasive strategy confers an increased risk
for both short-term and mid-term mortality (3–5). However,
few studies have evaluated the impact of in-hospital major
bleeding (IHMB) on longer-term outcomes in these patients.
Accordingly, we sought to evaluate the clinical correlates
and impact of IHMB on the 3-year outcomes after primary
percutaneous coronary intervention (PCI) for acute MI among
randomized participants in the HORIZONS-AMI (Harmo-
nizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial.
Baseline Clinical and Angiographic Characteristof Patients With With ut In-Hospital MajorTable 1 Baseli e Clin cal a d Angiograph cof Patients With and Without In-Ho
Age, yrs
Female
Body mass index, kg/m2
Anemia
WBC count, baseline, giga/l
Hypertension
Hyperlipidemia
Current smoking
Diabetes mellitus
Insulin dependent
Previous MI
Previous PCI
Previous CABG
History of CHF
Renal insufficiency
Periprocedural characteristics
Time from symptom onset to hospital arrival, h
Time from symptom onset to first balloon inflation, h
Killip class 2 to 4
Index PCI vessels
LAD
Index procedure
Balloon angioplasty only
Stent implanted
No. of stents, per patient
Stent total length, mm
Final TIMI flow grade after PCI
0–1
2
3
Values are median (interquartile range) or % (n/N).
CABG  coronary artery bypass graft; CHF  congestive heart failure; LAD
percutaneous coronary intervention; TIMI  Thrombolysis In Myocardial InfarMethods
The design of the HORIZONS-
AMI trial has been previously
described (4). Endpoints for the
current analysis included all-
cause mortality, the composite
endpoint of major adverse clini-
cal events (MACE) (composite
of death, reinfarction, target ves-
sel revascularization for ischemia,
or stroke), and stent thrombosis
(ST, definite, or probable) at
3-year follow-up. Major bleeding
was defined as the occurrence of
any of the following: intracranial bleeding, intraocular
bleeding, retroperitoneal bleeding, access site hemorrhage
requiring surgery or radiologic or interventional procedure,
hematoma 5 cm in diameter at the puncture site, reduc-
tion in hemoglobin concentration of 4 g/dl without an
ingacteristics
Major Bleeding
ajor Bleeding
(n  218)
No Major Bleeding
(n  3,114) p Value
50 (56.1–77.3) 59.7 (52.4–69.3) 0.0001
% (82/218) 21.9% (682/3,114) 0.0001
.3 (23.8–29.5) 27.1 (24.6–30.3) 0.01
% (42/227) 9.9% (289/2,926) 0.01
.0 (8.5–14.2) 10.9 (8.8–13.4) 0.21
% (125/218) 52.3% (1,629/3,112) 0.15
% (90/218) 43.0% (1,337/3,112) 0.63
% (86/215) 47.5% (1,471/3,100) 0.03
% (49/218) 15.9% (496/3,112) 0.01
% (14/218) 4.3% (135/3,112) 0.15
% (26/218) 10.4% (324/3,112) 0.48
% (23/218) 10.5% (327/3,111) 0.99
% (7/218) 2.6% (81/3,112) 0.59
% (11/218) 2.4% (75/3,112) 0.02
% (18/218) 2.4% (75/3,111) 0.0001
.5 (1.4–4.2) 2.1 (1.3–3.9) 0.10
.1 (3.0–5.8) 3.7 (2.7–5.6) 0.01
% (38/218) 7.9% (248/3,109) 0.0001
% (100/236) 40.6% (1,349/3,325) 0.59
% (16/215) 3.9% (120/3,056) 0.01
% (185/218) 94.1% (2,929/3,114) 0.0001
1.7 1.0 1.5 0.8 0.007
28 (20–44) 24 (20–36) 0.003
% (15/236) 2.0% (67/3,319) 0.0001
% (30/236) 5.5% (184/3,319) 0.0001
% (191/236) 92.4% (3,068/3,319) 0.0001
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
IHMB  in-hospital major
bleeding
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosisicsBleedChar
spital
M
67.
37.6
26
18.5
11
57.3
41.3
40.0
22.5
6.4
11.9
10.6
3.2
5.0
8.3
2
4
17.4
42.4
7.4
84.9
6.4
12.7
80.9 left anterior descending artery; MI  myocardial infarc
ction; WBC  white blood cell.tion; PCI 
I recept
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Impact of In-Hospital Bleeding on Late Outcome October 18, 2011:1750–6overt source of bleeding, reduction in hemoglobin concen-
tration of 3 g/dl with an overt source of bleeding,
reoperation for bleeding, or use of any blood product
Figure 1 Independent Predictors of In-Hospital Major Bleeding
Boxes represent odds ratios (ORs) and lines 95% confidence intervals (CIs). GPI 
Medication Use in Patients With and Without InTable 2 Medication Use in Patients With an
Major Bleeding (
Nonprotocol pre-procedure heparin 66.5% (145/
Use of GPI 76.0% (165/
Use of bivalirudin 34.9% (76/2
Clopidogrel loading dose given 97.7% (213/
300 mg 42.7% (93/2
600 mg 53.7% (117/
Aspirin use
At discharge 97.4% (188/
At 30 days 96.7% (178/
At 1 yr 94.0% (156/
At 3 yrs 95.3% (142/
Thienopyridine use
At discharge 96.9% (187/
At 30 days 96.8% (179/
At 1 yr 68.3% (114/
At 3 yrs 34.7% (52/1
Other medication at discharge
Beta-blocker 84.1% (180/
ACEIs or ARBs 81.9% (158/
Statin 90.2% (174/
Diuretics 30.6% (59/1
Digoxin 3.1% (6/19
Amiodarone 6.7% (13/1
Nonstatin lipid-lowering agent 5.2% (10/1
Warfarin 6.2% (12/1
Cilostazol 0.5% (1/19
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin Itransfusion (4). Bleeding complications were adjudicated as
either related or unrelated to coronary artery bypass
(CABG) graft surgery. An independent clinical events
gistic Regression
protein IIb/IIIa inhibitor.
pital Major Bleedingthout In-Hospital Major Bleeding
8) No Major Bleeding (n  3,114) p Value
65.6% (2,042/3,112) 0.79
54.6% (1,696/3,109) 0.0001
51.0% (1,582/3,102) 0.0001
98.1% (3,054/3,112) 0.60
33.3% (1,128/3,112) 0.005
63.4% (1,972/3,112) 0.004
98.8% (3,024/3,061) 0.10
98.1% (2,911/2,966) 0.17
97.2% (2,773/2,854) 0.02
95.4% (2,631/2,759) 0.97
98.1% (3,004/3,063) 0.28
97.3% (2,891/2,970) 0.64
69.8% (1,995/2,858) 0.67
26.9% (744/2,765) 0.04
91.1% (2,826/3,103) 0.0007
82.5% (2,527/3,063) 0.82
95.9% (2,938/3,063) 0.0002
20.6% (630/3,063) 0.001
1.1% (35/3,063) 0.03
2.3% (70/3,063) 0.001
4.3% (131/3,061) 0.55
3.6% (109/3,063) 0.06
0.6% (19/3,063) 1.0
or blocker; GPI  glycoprotein IIb/IIIa inhibitor.by Lo
glyco-Hosd Wi
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217)
18)
218)
18)
218)
193)
184)
166)
149)
193)
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93)
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October 18, 2011:1750–6 Impact of In-Hospital Bleeding on Late Outcomecommittee adjudicated all primary endpoints and ST events
throughout the 3-year follow-up period.
For the current analysis, we compared the 3-year clinical
outcomes in patients with a non–CABG-related major
bleeding event as their first in-hospital adverse event after
the index procedure with patients who did not have major
bleeding during their hospital course.
Statistical methods. Categorical variables are presented as
percentages and were compared with the chi-square test or
Fisher exact test. Continuous variables are presented as
medians with interquartile ranges and were compared using
Mann-Whitney U test.
Predictors of IHMB were identified with logistic regression
analyses. The following variables were entered: age, female sex,
body mass index, hypertension, hyperlipidemia, smoking, dia-
betes, previous MI, previous CABG, previous angina, previous
heart failure, baseline thrombocytopenia, baseline anemia,
renal insufficiency (defined as estimated glomerular filtration
rate 60 ml/min), use of pre-randomization heparin, anti-
platelet medication use in the past 5 days, pharmacologic
randomization arm, loading dose of clopidogrel, symptom to
balloon time, and culprit lesion in left anterior descending artery.
Rates of clinical endpoints were compared between pa-
tients with and without IHMB cumulative to 3 years and
within 3 separate time intervals (0 to 30 days, 30 days to 1
year, and 1 to 3 years). The results are displayed using
Kaplan-Meier estimates and compared using the log-rank
test.
Cox proportional hazards analysis was used to identify
independent predictors of 3-year mortality. The multivariate
model was built by stepwise variable selection with entry and
exit criteria set at the p 0.1 level, and we selected all relevant
variables from previous studies as candidate variables for this
model. Variables included in the multivariable model were age,
sex, diabetes mellitus, Killip class, baseline anemia, white blood
cell count, renal insufficiency, hypertension, hyperlipidemia,
previous MI, smoking, pharmacologic randomization arm,
loading dose of clopidogrel, culprit lesion in left anterior
descending artery, symptom to first balloon time, and final
Thrombolysis In Myocardial Infarction flow grade 3. IHMB
and in-hospital ST were forced into the outcomes model.
As a secondary analysis, Cox proportional hazards analysis
was repeated for in-hospital survivors only. In addition to the
same variables used in the previous model, we included
prescription of a statin, beta-blocker, or a thienopyridine at
discharge as variables in this model. A p value 0.05 was
onsidered statistically significant.
esults
atient characteristics. Primary PCI was performed in
,345 (92.9%) of 3,602 randomized patients; in-hospital
rotocol-defined non–CABG-related major bleeding devel-
ped in 231 (6.9%). Thirteen cases were excluded because the
leeding events developed after thrombotic complications (re-
nfarction, n  1; stroke, n  1; ischemic target vesselevascularization, n  2; or ST, n  9). Table 1 shows the
aseline clinical, angiographic, and procedural characteristics of
atients. Patients with IHMB were older, more often female,
ore often had a history of congestive heart failure, had a
igher Killip class, and had a lower body mass index. More-
ver, they were more likely to have diabetes mellitus, anemia,
nd renal insufficiency. IHMB occurred less frequently in
atients randomized to bivalirudin. Table 2 shows antithrom-
otic medication use in patients. A 600-mg loading dose of
lopidogrel and bivalirudin was administered less frequently,
nd glycoprotein IIb/IIIa inhibitors were more often used in
atients with bleeding. Independent predictors of IHMB are
resented in Figure 1.
edications use at and after discharge. As shown in Table 2,
here were no significant differences in the prescription rate of
Cumulative Rates of Major Adverse Clinical Eventsin Patients With Versus WithoutI -Hospital M jor Bleeding
Table 3
Cumulative Ra es of Major Advers Clinical Events
in Patients With Versus Without
In-Hospital Major Bleeding
Major Bleeding
(n  218)
No Major Bleeding
(n  3,114) p Value
MACE
3 yrs, cumulative 40.3% (85) 20.5% (622) 0.0001
30 days 14.7% (32) 4.4% (136) 0.0001
30 days to 1 yr 16.2% (31) 6.7% (201) 0.0001
1 to 3 yrs 21.8% (36) 11.2% (324) 0.0001
Death
3 yrs, cumulative 24.6% (52) 5.4% (163) 0.0001
30 days 11.0% (24) 1.8% (57) 0.0001
30 days to 1 yr 7.3% (14) 1.3% (38) 0.0001
1 to 3 yrs 8.5% (14) 2.4% (68) 0.0001
Cardiovascular death
3 yrs, cumulative 14.2% (30) 3.2% (97) 0.0001
30 days 9.7% (21) 1.8% (55) 0.0001
30 days to 1 yr 3.2% (6) 0.5% (15) 0.0001
1 to 3 yrs 1.9% (3) 1.0% (27) 0.25
Myocardial infarction
3 yrs, cumulative 11.2% (22) 7.1% (209) 0.02
30 days 1.0% (2) 1.7% (53) 0.40
30 days to 1 yr 3.2% (6) 2.2% (66) 0.34
1 to 3 yrs 5.1% (8) 3.6% (101) 0.36
Ischemic TVR
3 yrs, cumulative 19.9% (39) 13.4% (398) 0.01
30 days 2.4% (5) 2.2% (67) 0.85
30 days to 1 yr 7.6% (14) 4.5% (136) 0.053
1 to 3 yrs 10.6% (17) 7.4% (213) 0.19
Stroke
3 yrs, cumulative 5.0% (10) 1.4% (41) 0.0001
30 days 1.4% (3) 0.4% (13) 0.04
30 days to 1 yr 1.6% (3) 0.4% (11) 0.01
1 to 3 yrs 1.9% (3) 0.6% (18) 0.07
Stent thrombosis
3 yrs, cumulative 7.0% (12) 4.7% (135) 0.18
30 days 3.1% (6) 2.1% (61) 0.33
30 days to 1 yr 1.8% (3) 1.0% (29) 0.34
1 to 3 yrs 2.7% (4) 1.7% (48) 0.40
Values are % (n).
MACE  major adverse cardiac events (composite of death, myocardial infarction, ischemic
target vessel revascularization and stroke); TVR  target vessel revascularization.
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1 month, and 3 years. At 1 year, however, patients with
bleeding were less likely to be taking aspirin. There were no
significant differences in thienopyridine use between both
groups at discharge, 1 year, and 2 years. However, patients with
IHMB were more likely to be taking a thienopyridine at 3
years. Patients with IHMB were less likely to receive a
beta-blocker and statin at hospital discharge, but were more
likely to receive diuretics, digoxin, and antiarrhythmic agents.
Major bleeding and clinical outcomes. Kaplan-Meier es-
timates of the incidence of MACE and their individual
components at 3 years and between 0 to 30 days, 30 days to 1
year, and 1 to 3 years are shown in Table 3. Patients with
IHMB had significantly higher 3-year rates of mortality
(24.6% vs. 5.4%, p 0.0001) (Fig. 2A) and MACE (40.3% vs.
20.5%, p  0.0001) (Fig. 2B).
Moreover, the rates of mortality and MACE were sig-
nificantly higher in patients with IHMB within each time
interval (Fig. 3). The 3-year cumulative rates of MI,
ischemic target vessel revascularization, and stroke were also
significantly higher in patients with IHMB. Rates of stroke
were significantly higher in the bleeding group within 30
days and between 30 days to 1 year, but not thereafter
(Table 3). The 3-year cumulative rates of ST were not
significantly increased in patients with compared to those
without IHMB.
IHMB was still associated with 3-year mortality (Online
Fig. A) and MACE (Online Fig. B) after exclusion of
patients with large hematomas alone (n  13).
Predictors of long-term mortality. IHMB was an indepen-
Figure 2 3-Year Mortality and MACE
Kaplan-Meier estimates of time to death (A) and major adverse cardiovascular eve
CI  confidence interval; HR  hazard ratio; MACE  major adverse cardiovasculadent predictor of 3-year mortality (hazard ratio [HR]: 2.80,95% confidence interval [CI]: 1.89 to 4.16; p 0.0001). Other
independent predictors included in-hospital ST, age, male sex,
diabetes mellitus, renal insufficiency, smoking, Killip classes 2
to 4 at admission, anemia, baseline white blood cell count, left
anterior descending artery culprit lesion, and final Thrombol-
ysis In Myocardial Infarction flow grade 3 (Table 4).
In the secondary analysis among in-hospital survivors
(n  3,260), IHMB remained an independent predictor of
3-year mortality (HR: 2.26, 95% CI: 1.43 to 3.54; p 
0.0004), while in-hospital ST was not a significant predictor
(HR: 0.95; 95% CI: 0.13 to 6.93).
Discussion
In the present analysis from the HORIZONS-AMI trial,
we found that the occurrence of IHMB in ST-segment
elevation myocardial infarction patients treated with pri-
mary PCI confers a sustained risk of both mortality and
MACE for at least 3 years. We also identified several
important differences in pharmacotherapy at the time of
discharge between patients with and without IHMB that
may in part explain the effect on late mortality.
Although the incidence of both mortality and MACE
among bleeding patients was greatest in the first 30 days
following PCI, the risk of late mortality after IHMB
continued to monotonically accrue over time. While the
deleterious impact of thrombotic complications is princi-
pally evidenced in the acute stage after their occurrence (6),
our findings do not suggest a similar attenuation of risk over
) in patients with and without in-hospital major bleeding.
ts.nts (B
r eventime in patients with IHMB in the setting of STEMI.
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October 18, 2011:1750–6 Impact of In-Hospital Bleeding on Late OutcomeIndeed, IHMB was associated with an approximate 3.5-fold
increased risk of mortality between 1 and 3 years.
In this study, IHMB was adjudicated according to the protocol
definition used in the HORIZONS-AMI and ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy) trials
(3,7). This report, therefore, validates the definition of major
bleeding used in these studies as being clinically relevant and useful
in predicting long-term prognosis.
The incidence of IHMB in the present study is higher
than that reported from earlier analyses in other acute
Patients with
Patients with
HR (95% CI) =
6.22 (3.86-10.0), p<0.001
D
ea
th
 (
%
)
Number at risk
218
3114  
Bleeding
No Bleeding
193
3035  
182
2987  
Number at risk   
218
3114  
Bleeding
No Bleeding 
185
2957  
167
2825  
Patients with I
Patients witho
HR (95% CI) =
3.48 (2.36-5.11), p<0.001
M
A
C
E
 (
%
)
A
B
Figure 3 3-Year Mortality and MACE at Different Time Intervals
(A) Mortality within 1 month, between 1 month and 1 year, and between 1 and 3
and between 1 and 3 years. Abbreviations as in Figure 2.coronary syndrome studies (1,8). Differences in patient pop-ulations, treatment strategies, and bleeding definitions likely
explain these discrepancies. Using the same protocol definition,
the rate of IHMB among acute coronary syndrome patients
treated with PCI in the ACUITY trial was 5.9% (9).
IHMB was associated with 3-year mortality and MACE after
the exclusion of patients with large hematomas alone, and the
influence of single large hematoma on subsequent mortality or
MACE seems to be negligible, as in previous reports (10,11).
Bleeding complications after acute MI may have detrimental
effects on long-term prognosis due to several reasons. Patients
ospital Major Bleeding
n-Hospital Major Bleeding
HR (95% CI) =
3.25-11.1), p<0.001
HR (95% CI) =
3.67 (2.00-6.52), p<0.001
175
2943  
159
2849  
98
1923 
154
2721  
131
2459  
74
1609 
pital Major Bleeding
Hospital Major Bleeding
 (95% CI) =
0-3.59), p<0.001
HR (95% CI) =
1.63 (1.09-2.43), p=0.02
dmark Analysis)
(B) MACE within 1 month, between 1 month and 1 year, In-H
out I
6.00 (
n-Hos
ut In-
HR
2.40 (1.6
(Lan
years.with IHMB were discharged less often on beta-blocker and
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acute MI (12). Interestingly, we did not find a reduction in the
use of antiplatelet agents in patients with IHMB, as has been
reported in the PREMIER (Prospective Registry Evaluating
Myocardial Infarction: Events and Recovery) registry (13). We
speculate that this may be due to mandated, protocol-defined
instructions to keep patients on dual antiplatelet therapy at
discharge and for up to at least 1 year. Greater comorbidities in
bleeding patients might have also contributed to higher car-
diovascular risk. IHMB remained a strong and independent
predictor of subsequent mortality, however, even after adjust-
ing for these differences. Other mechanisms that might
heighten cardiac risk after bleeding include hypovolemia,
hypotension, anemia, impaired oxygen-carrying capacity, and
inflammatory response caused by transfusion (3). These factors
generate multiple hypotheses for future investigation.
Study limitations. The current analysis was not pre-
specified in the original study. Multivariate analysis might
not account for unmeasured confounders that are associated
with mortality after acute MI.
Conclusions
IHMB confers an independent and sustained risk of both
mortality and MACE in patients with ST-segment elevation
myocardial infarction treated with primary PCI. Further in-
Independent Predictors of 3-Year Mortality AfterPrimary PCI in All Patients and In-H spital SurvivorsTable 4 I d pendent Predictors of 3-Year Mortality AfterPrimary PCI in All Patients and In-Hospital Survivors
HR (95% CI) p Value
All patients
In-hospital major bleeding 2.80 (1.89–4.16) 0.0001
In-hospital stent thrombosis 13.0 (6.95–24.3) 0.0001
Age, every 10-yr increase 1.93 (1.59–2.33) 0.0001
Male 1.53 (1.06–2.22) 0.02
Diabetes 1.65 (1.17–2.34) 0.004
Renal insufficiency 1.57 (1.06–2.32) 0.02
History of smoking 1.67 (1.18–2.36) 0.004
Anemia at admission 1.79 (1.21–2.65) 0.004
WBC count at admission, per 1 giga/l 1.08 (1.04–1.12) 0.0001
Killip class 2 to 4 2.04 (1.40–2.96) 0.0002
Culprit lesion in LAD 1.64 (1.08–2.49) 0.02
Final TIMI flow grade 3 count 0.57 (0.40–0.83) 0.003
Hospital survivors
In-hospital major bleeding 2.29 (1.43–3.67) 0.0006
Age, every 10-yr increase 2.22 (1.85–2.66) 0.0001
Diabetes 1.76 (1.19–2.60) 0.004
History of smoking 1.96 (1.33–2.90) 0.0007
Anemia at admission 2.00 (1.31–3.06) 0.001
WBC count at admission, per 1 giga/l 1.08 (1.04–1.14) 0.0006
Culprit lesion in LAD 1.73 (1.10–2.71) 0.02
Statin prescription at discharge 0.49 (0.26–0.90) 0.02
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.vestigation is warranted to understand the mechanisms under-lying this relationship and whether the prognosis of these
patients may be improved by tailored follow-up and detailed
attention to adjunctive pharmacotherapy.
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